Change of Range of Motion of TMJ After Correction of Pelvic a Symmetry in Women With Cyclic Pelvic Pain


Clinical experiences have shown that significant pain regression during a menstrual cycle has been often achieved by the use of spinal manipulative therapy (SMT) indicated in women with primary dysmenorrhea with coexisting functional disorders of lumbosacral (LS) spine. Namely, by activation of the nociceptive and vegetative system, LS spine disorders, before all segmental dysfunction and degenerative changes, can induce referred pain and reflex disturbances of pelvic organs (somatovisceral reflexes). Since significant improvement or disappearance of pain during a menstrual cycle is often achieved with adequate therapy of coexisting vertebral disorders in women with primary dysmenorrhea, it is important to recognise latent or manifest vertebral disorders in dysmenorrheic women using clinical examination (Grgić, 2009).

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: August 1, 2020


  • Other: muscle energy technique
    • Muscle energy technique: Application of MET for bone of pelvis: I) Pubis: Cranial Os pubis. Caudal os pubis. II) ileum: Anterior ileum. Posterior ileum. External Rotation (In flare) Lesion. Internal Rotation (Out flare) Lesion. III) sacrum: Forward torsion of sacrum. Backward torsion of sacrum. Muscle energy technique for specific muscles of pelvis and spine: Stretch of the Psoas Major. Stretch of the paravertebral muscle. Stretch of the piriforms.

Arms, Groups and Cohorts

  • Study group (group A):
    • It consisted of fifteen subjects who received muscle energy technique (Mitchell relaxation osteopathic technique). Two sessions per cycle for three cycles before menstruation by one week and after the end of menstruation by one week. In addition to their medical treatment non-steroidal anti-inflammatory drugs (NIAIDS).
  • control group (group B):
    • It consisted of fifteen subjects who took their medical treatment only (non-steroidal anti-inflammatory drugs (NIAIDS)).

Clinical Trial Outcome Measures

Primary Measures

  • Weight-Height Scale
    • Time Frame: 3 months
    • It will be used for measuring the body weight and height of each patient participating in the study to calculate the patient’s body mass index (BMI). Body mass index (BMI) = Weight (Kg
  • Visual analogue scale (VAS)
    • Time Frame: 3 months
    • ain will be assessed by visual analogue scale. It is 10 cm horizontal line with one end described as (no pain=0) and other end (worst pain=10). It was considered a valid way for assessing pain. It allowed graphic representation and numerical analysis of collected data (Boonstra et al., 2008) (Appendix III).
  • Menstrual Distress Questionnaire (MDQ)
    • Time Frame: 3 months
    • The MDQ is a 46-item self-report inventory for use in the assessment and treatment of premenstrual and menstrual symptoms. The MDQ can distinguish cyclical from noncyclical changes in physical symptoms, mood and behavior, and arousal.
  • jaw movement
    • Time Frame: 3 months
    • Maximal vertical mouth opening (MIO): From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor. The distance recorded in millimeters, the subjects was instructed to” open your mouth as wide as possible without causing pain or discomfort”. The poley gauge was sterilized with antiseptic solution before and after each measur

Participating in This Clinical Trial

Inclusion Criteria

  • The age of the participants will be ranged from 25 to 35 years.
  • Their body mass index will be ranged from 20 to 25 kg/m2.
  • They will have regular menstrual cycle.
  • They will not receive any hormonal therapy or taking any regular drugs.

Exclusion Criteria

The potential participants will be excluded if they meet one of the following criteria:

  • Pelvic inflammatory diseases.
  • Any pelvic pathological condition

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Cairo University
  • Provider of Information About this Clinical Study
    • Principal Investigator: HAhmed, assistant proffesor – Cairo University
  • Overall Contact(s)
    • rovan m elbesh, master, 01006272174,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.